Halozyme Therapeutics, Inc.
HALO
Classifica tra le azioni
#1547
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Prezzo delle azioni
$123.84
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$14.06B
Variazione (1 giorno)
1.09%
Variazione (1 anno)
85.17%
Paese
US
Scambia Halozyme Therapeutics, Inc. (HALO)
Categoria
Healthcare
Utile per Halozyme Therapeutics, Inc. (HALO)
Utile nel Jun 2026 TTM: $583.34M
Secondo gli ultimi rapporti finanziari di Halozyme Therapeutics, Inc., gli utili attuali della società sono $583.34M. Nel 2023, la società ha registrato un utile di $348.33M, un aumento rispetto a agli utili del 2022, che erano di $248.92M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Halozyme Therapeutics, Inc. dal 2001 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $583.34M | 4.70% |
| 2024 | $557.13M | 59.94% |
| 2023 | $348.33M | 39.94% |
| 2022 | $248.92M | 0.16% |
| 2021 | $248.52M | 92.20% |
| 2020 | $129.30M | -278.96% |
| 2019 | $-72.25M | -9.45% |
| 2018 | $-79.79M | -229.51% |
| 2017 | $61.61M | -160.48% |
| 2016 | $-101.86M | 216.03% |
| 2015 | $-32.23M | -52.86% |
| 2014 | $-68.38M | -18.09% |
| 2013 | $-83.48M | 55.88% |
| 2012 | $-53.55M | -99.73% |
| 2011 | $-19.77B | 37,032.30% |
| 2010 | $-53.24M | -8.77% |
| 2009 | $-58.36M | 19.79% |
| 2008 | $-48.72M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $-13.28M | 46.02% |
| 2004 | $-9.09M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-64.46K | 62.57% |
| 2001 | $-39.65K | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 804.26% |
US
|
|
| $-3.09B | -629.20% |
US
|
|
| $-4.02B | -788.49% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 234.39% |
NL
|
